Literature DB >> 27074625

Development and Characterization of a Potent Free Fatty Acid Receptor 1 (FFA1) Fluorescent Tracer.

Elisabeth Christiansen1, Brian D Hudson2, Anders Højgaard Hansen1, Graeme Milligan2, Trond Ulven1.   

Abstract

The free fatty acid receptor 1 (FFA1/GPR40) is a potential target for treatment of type 2 diabetes. Although several potent agonists have been described, there remains a strong need for suitable tracers to interrogate ligand binding to this receptor. We address this by exploring fluorophore-tethering to known potent FFA1 agonists. This led to the development of 4, a high affinity FFA1 tracer with favorable and polarity-dependent fluorescent properties. A close to ideal overlap between the emission spectrum of the NanoLuciferase receptor tag and the excitation spectrum of 4 enabled the establishment of a homogeneous BRET-based binding assay suitable for both detailed kinetic studies and high throughput competition binding studies. Using 4 as a tracer demonstrated that the compound acts fully competitively with selected synthetic agonists but not with lauric acid and allowed for the characterization of binding affinities of a diverse selection of known FFA1 agonists, indicating that 4 will be a valuable tool for future studies at FFA1.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27074625     DOI: 10.1021/acs.jmedchem.6b00202

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  8 in total

1.  Using a GFP-tagged TMEM184A Construct for Confirmation of Heparin Receptor Identity.

Authors:  Sara Lynn N Farwell; Joshua B Slee; Yaqiu Li; Linda J Lowe-Krentz
Journal:  J Vis Exp       Date:  2017-02-17       Impact factor: 1.355

Review 2.  Fluorescent ligands: Bringing light to emerging GPCR paradigms.

Authors:  Mark Soave; Stephen J Briddon; Stephen J Hill; Leigh A Stoddart
Journal:  Br J Pharmacol       Date:  2020-02-06       Impact factor: 8.739

3.  Which one of LDL-C /HDL-C ratio and non-HDL-C can better predict the severity of coronary artery disease in STEMI patients.

Authors:  Po Gao; Xiang Wen; Qiaoyun Ou; Jing Zhang
Journal:  BMC Cardiovasc Disord       Date:  2022-07-17       Impact factor: 2.174

4.  Synthesis and Evaluation of the First Fluorescent Antagonists of the Human P2Y2 Receptor Based on AR-C118925.

Authors:  Sean Conroy; Nicholas D Kindon; Jacqueline Glenn; Leigh A Stoddart; Richard J Lewis; Stephen J Hill; Barrie Kellam; Michael J Stocks
Journal:  J Med Chem       Date:  2018-03-28       Impact factor: 7.446

5.  Fluorescent ligands for dopamine D2/D3 receptors.

Authors:  Anni Allikalt; Nirupam Purkayastha; Khajidmaa Flad; Maximilian F Schmidt; Alina Tabor; Peter Gmeiner; Harald Hübner; Dorothee Weikert
Journal:  Sci Rep       Date:  2020-12-14       Impact factor: 4.379

6.  Association of Coronary Artery Disease and Metabolic Syndrome: Usefulness of Serum Metabolomics Approach.

Authors:  Ziwei Jing; Liwei Liu; Yingying Shi; Qiuzheng Du; Dingding Zhang; Lihua Zuo; Shuzhang Du; Zhi Sun; Xiaojian Zhang
Journal:  Front Endocrinol (Lausanne)       Date:  2021-09-24       Impact factor: 5.555

7.  Fluorescent Ligand-Based Discovery of Small-Molecule Sulfonamide Agonists for GPR120.

Authors:  Siyue Ma; Zhenzhen Li; Yueli Yang; Ling Zhang; Minyong Li; Lupei Du
Journal:  Front Chem       Date:  2022-01-31       Impact factor: 5.221

Review 8.  Coelenterazine-Dependent Luciferases as a Powerful Analytical Tool for Research and Biomedical Applications.

Authors:  Vasilisa V Krasitskaya; Eugenia E Bashmakova; Ludmila A Frank
Journal:  Int J Mol Sci       Date:  2020-10-10       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.